Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00219232 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
July 31, 2006
Enrollment
868 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease